CoChat

Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast Cancer

Wynne, Chris, Harvey, Vernon, Schwabe, Christian, Waaka, Devonie, McIntyre, Christine, Bittner, Beate · 2013 · The Journal of Clinical Pharmacology
Cited by 128

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Trastuzumab is a key component of treatment for human epidermal growth factor receptor 2 (HER2)–positive breast cancer in both the early and metastatic settings. It is administered intravenously, with between 17 and 52 infusions in standard regimens over 1 year. Intravenous administration of trastuzumab requires substantial time commitments for patients and health care professionals and can result in patient discomfort. A subcutaneous formulation of trastuzumab, containing recombinant human hyaluronidase to overcome subcutaneous absorption barriers, would reduce the administration duration and remove the need to establish intravenous access, thus improving the overall convenience of trastuzumab administration. This open‐label, 2‐part, phase I/Ib study (NCT00800436) was undertaken in healthy male volunteers and female patients with HER2‐positive early breast cancer to identify the dose of subcutaneous trastuzumab that resulted in exposure comparable with the approved intravenous trastuzumab dose. A subcutaneous trastuzumab dose of 8 mg/kg was found to result in exposure comparable with the intravenous trastuzumab dose of 6 mg/kg. The subcutaneous formulation was well tolerated, with a trend toward fewer adverse events versus intravenous administration; most adverse events were mild in intensity. These results support an ongoing phase III efficacy and safety study comparing a fixed subcutaneous trastuzumab dose with intravenous trastuzumab administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0091270012436560

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 14

  1. 10.1126/science.3798106 · DOI · Paper page
  2. 10.1002/cncr.25120 · DOI
  3. 10.1634/theoncologist.2008-0230 · DOI · Paper page
  4. 10.1016/S1470-2045(11)70033-X · DOI · Paper page
  5. 10.1200/JCO.2011.35.0868 · DOI · Paper page
  6. 10.1056/NEJM200103153441101 · DOI · Paper page
  7. 10.1200/JCO.2005.04.173 · DOI · Paper page
  8. 10.1016/S0140-6736(10)61121-X · DOI · Paper page
  9. 10.1080/10428190903150839 · DOI
  10. 10.1113/expphysiol.1991.sp003536 · DOI · Paper page
  11. 10.1517/14712590903490382 · DOI
  12. 10.1016/j.jconrel.2006.05.027 · DOI · Paper page
  13. VelagapudiR NoertershauserP AwniW GrannemanR KupperH.Bioavailability of Adalimumab Following Subcutaneous Injections in Rheumatoid Arthritis Patients. Alexandria VA: American Society for Clinical Pharmacology and Therapeutics; 2005. · DOI
  14. 10.1007/s00280-005-1026-z · DOI · Paper page

Cited by

See all 128

Metadata

Authors
Wynne, C., Harvey, V., Schwabe, C., Waaka, D., McIntyre, C., & Bittner, B.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2013-02
Volume
53
Issue
2
Pages
192-201
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W1906683030
Cited by
128
References
4
FWCI
6.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast Cancer. https://app.cochat.ai/papers/10.1177/0091270012436560
The paper
Wynne, C., Harvey, V., Schwabe, C., Waaka, D., McIntyre, C., & Bittner, B. (2013). Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast Cancer. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270012436560

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.